Promotion of classic neutral bile acids synthesis pathway is responsible for cholesterol-lowing effect of Si-miao-yong-an decoction: Application of LC–MS/MS method to determine 6 major bile acids in rat liver and plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 135, Issue , 2017, Pages 167-175

  Liu, Ziying ^a   Zhang, Yu ^a   Zhang, Ruowen ^b   Gu, Liqiang ^a   Chen, Xiaohui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

ALT; AST; Bile acids; CA; CDCA; chenodeoxycholic acid; cholic acid; GCA; GCDCA; glutamic oxalacetic transaminase; glutamic pyruvic transaminase; glyco chenodeoxycholic acid; glycocholic acid; HDL c; high density lipoprotein cholesterol; Hyperlipidemia; LC MS MS; LDL c; low density lipoprotein cholesterol; Si miao yong an decoction; SMYAD; taurochenodeoxycholic acid; taurocholic acid; TC; TCA; TCDCA; TCM; TG; total cholesterol; total triglyceride; traditional Chinese medicine

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHENODEOXYCHOLIC ACID; CHOLIC ACID; GLYCOCHOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT MEDICINAL PRODUCT; SI MIAO YONG AN DECOCTION; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; BILE ACID; CHOLESTEROL; HERBACEOUS AGENT; HYPOCHOLESTEROLEMIC AGENT;

ANGELICA SINENSIS; ANIMAL EXPERIMENT; ARTICLE; BILE ACID SYNTHESIS; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERLIPIDEMIA; IN VIVO STUDY; ION MONITORING; LIMIT OF QUANTITATION; LIPID DIET; LIPID STORAGE; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIVER; LIVER FUNCTION TEST; LONICERA JAPONICA; MASS FRAGMENTOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE SECTION; TREATMENT OUTCOME; ANIMAL; BLOOD; DRUG EFFECTS; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PLASMA; PROCEDURES; RANDOMIZATION; SPRAGUE DAWLEY RAT; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; CHOLESTEROL; CHROMATOGRAPHY, LIQUID; DRUGS, CHINESE HERBAL; LIVER; MALE; METABOLIC NETWORKS AND PATHWAYS; PLASMA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 85007174666     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2016.12.021     Document Type: Article

References (56)

1. [1] Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., Das, S.R., de Ferranti, S., Després, J.-P., Fullerton, H.J., Executive summary: heart disease and stroke statistics—2016 update a report from the american heart association. Circulation 133 (2016), 447–454.
2. [2] Wang, N., Tall, A.R., Cholesterol in platelet biogenesis and activation. Blood, 2016 blood-2016-2001-631259.
3. [3] Zechariah, A., ElAli, A., Hagemann, N., Jin, F., Doeppner, T.R., Helfrich, I., Mies, G., Hermann, D.M., Hyperlipidemia attenuates vascular endothelial growth factor?induced angiogenesis, impairs cerebral blood flow, and disturbs stroke recovery via decreased pericyte coverage of brain endothelial cells. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 1561–1567.
4. [4] Kawada, T., Body mass index is a good predictor of hypertension and hyperlipidemia in a rural Japanese population. Int. J. Obes. Relat. Metabo. Disord., 26, 2002.
5. [5] Golabi, P., Otgonsuren, M., Cable, R., Felix, S., Koenig, A., Sayiner, M., Younossi, Z.M., Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQOL). Health Qual. Life Outcomes, 14, 2016, 1.
6. [6] Istvan, E.S., Structural mechanism for statin inhibition of HMG-CoA reductase, J. Deisenhofer. Science 292 (2001), 1160–1164.
7. [7] Insull, W. Jr., Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South. Med. J. 99 (2006), 257–274.
8. [8] Chang, T.-Y., Chang, C., Ezetimibe blocks internalization of the NPC1L1/cholesterol complex. Cell Metab. 7 (2008), 469–471.
9. [9] Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., Fruchart, J.-C., Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998), 2088–2093.
10. [10] Moosmann, B., Behl, C., Selenoprotein synthesis and side-effects of statins. Lancet 363 (2004), 892–894.
11. [11] Stolk, M.F., Becx, M.C., Kuypers, K.C., Seldenrijk, C.A., Severe hepatic side effects of ezetimibe. Clin. Gastroenterol. Hepatol. 4 (2006), 908–911.
12. [12] Maggo, M.S.D., Kennedy, M.A., Clark, D.W., Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf. 34 (2011), 1–19.
13. [13] Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S.J., Grobbee, D.E., Cass, A., Chalmers, J., Perkovic, V., Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375 (2010), 1875–1884.
14. [14] Wierzbicki, A.S., Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr. Opin. Cardiol. 24 (2009), 372–379.
15. [15] Filippatos, T., Mikhailidis, D., Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr. Pharm. Des. 15 (2009), 490–516.
16. [16] Lu, A., Jiang, M., Zhang, C., Chan, K., An integrative approach of linking traditional Chinese medicine pattern classification and biomedicine diagnosis. J. Ethnopharmacol. 141 (2012), 549–556.
17. [17] Qiu, J., Traditional medicine: a culture in the balanceNature, Vol.448, 2007, 126–128.
18. [18] Yin, J., Zhang, H., Ye, J., Endocrine traditional chinese medicine in treatment of metabolic syndrome, metabolic & immune disorders-drug targets. Formerly Curr. Drug Targets Immun. Endocr. Metab. Disord. 8 (2008), 99–111.
19. [19] Sui, Y., Zhao, H., Wong, V., Brown, N., Li, X., Kwan, A., Hui, H., Ziea, E., Chan, J., A systematic review on use of Chinese medicine and acupuncture for treatment of obesity. Obes. Rev. 13 (2012), 409–430.
20. [20] Li, W., Zheng, H., Bukuru, J., De Kimpe, N., Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J. Ethnopharmacol. 92 (2004), 1–21.
21. [21] Dou, X.-b., Wo, X.-d., Fan, C.-l, Progress of research in treatment of hyperlipidemia by monomer or compound recipe of Chinese herbal medicine. Chin. J. Integr. Med. 14 (2008), 71–75.
22. [22] Liu, Z.L., Liu, J.P., Zhang, A.L., Wu, Q., Ruan, Y., Lewith, G., Visconte, D., Chinese Herbal Medicines for Hypercholesterolemia. 2011, The Cochrane Library.
23. [23] Xie, W., Zhao, Y., Du, L., Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. J. Ethnopharmacol. 140 (2012), 345–367.
24. [24] Wong, T., Wong, S., Donnan, S.P., Traditional Chinese medicine and Western medicine in Hong Kong: a comparison of the consultation processes and side effects. J. Hong Kong Med. Assoc. 45 (1993), 278–284.
25. [25] Yu, L., Li, Y., Fan, H., Duan, J., Zhu, Q., Li, S., Analysis of marker compounds with anti-platelet aggregation effects in mailuoning injection using platelet binding assay combined with HPLC-DAD-ESI–MS and solid‐phase extraction technique. Phytochem. Anal. 22 (2011), 87–93.
26. [26] Peng, L., Li, M., Xu, Y.Z., Zhang, G.Y., Yang, C., Zhou, Y.N., Li, L.J., Zhang, J.P., Effect of Si-Miao-Yong-An on the stability of atherosclerotic plaque in a diet-induced rabbit model. J. Ethnopharmacol. 143 (2012), 241–248.
27. [27] Trauner, M., Claudel, T., Fickert, P., Moustafa, T., Wagner, M., Bile acids as regulators of hepatic lipid and glucose metabolism. Dig. Dis. 28 (2010), 220–224.
28. [28] Hylemon, P.B., Zhou, H., Pandak, W.M., Ren, S., Gil, G., Dent, P., Bile acids as regulatory molecules. J. Lipid Res. 50 (2009), 1509–1520.
29. [29] Gupta, S., Stravitz, R.T., Dent, P., Hylemon, P.B., Down-regulation of cholesterol 7α-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J. Biol. Chem. 276 (2001), 15816–15822.
30. [30] Griffiths, W.J., Sjövall, J., Bile acids: analysis in biological fluids and tissues. J. Lipid Res. 51 (2010), 23–41.
31. [31] Garcia-Canaveras, J.C., Donato, M.T., Castell, J.V., Lahoz, A., Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J. Lipid Res. 53 (2012), 2231–2241.
32. [32] Han, J., Liu, Y., Wang, R., Yang, J., Ling, V., Borchers, C.H., Metabolic profiling of bile acids in human and mouse blood by LC-MS/MS in combination with phospholipid-depletion solid-phase extraction. Anal. Chem. 87 (2015), 1127–1136.
33. [33] Minato, K., Suzuki, M., Nagao, H., Suzuki, R., Ochiai, H., Development of analytical method for simultaneous determination of five rodent unique bile acids in rat plasma using ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 1002 (2015), 399–410.
34. [34] Huang, J., Bathena, S.P., Csanaky, I.L., Alnouti, Y., Simultaneous characterization of bile acids and their sulfate metabolites in mouse liver, plasma, bile, and urine using LC–MS/MS. J. Pharm. Biomed. Anal. 55 (2011), 1111–1119.
35. [35] Stedman, C., Robertson, G., Coulter, S., CLiddle, C., Liddle feed-forward regulation of bile acid detoxification by CYP3A4 STUDIES IN HUMANIZED TRANSGENIC MICE. J. Biol. Chem. 279:12 (2004), 11336–11343.
36. [36] Tagliacozzi, D., Mozzi, A.F., Casetta, B., Bertucci, P., Bernardini, S., Di Ilio, C., Urbani, A., Federici, G., Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin. Chem. Lab. Med. 41 (2003), 1633–1641.
37. [37] Garcia-Canaveras, J.C., Donato, M.T., Castell, J.V., Lahoz, A., Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res. 5 3 (2012), 2231–2241.
38. [38] Warrack, B.M., DiDonato, G.C., Ion spray liquid chromatographic/mass spectrometric characterization of bile acids. Biol. Mass Spectrom. 22 (1993), 101–111.
39. [39] Huang, J., Bathena, S.P.R., Csanaky, I.L., Alnouti, Y., Simultaneous characterization of bile acids and their sulfate metabolites in mouse liver, plasma, bile, and urine using LC–MS/MS. J. Pharm. Biomed. Anal. 55:5 (2011), 1111–1119.
40. [40] Lee, B.L., New, A.L., Ong, C.N., Comparative analysis of conjugated bile acids in human serum using high-performance liquid chromatography and capillary electrophoresis. J. Chromatogr. B: Biomed. Sci. Appl. 704 (1997), 35–42.
41. [41] Roda, A., Gioacchini, A.M., Cerre, C., Baraldini, M., High-performance liquid chromatographic-electrospray mass spectrometric analysis of bile acids in biological fluids. J. Chromatogr. B: Biomed. Appl. 665 (1995), 281–294.
42. [42] U.S. Department of Health and Human Services, Food and Drug Administration Guidance for Industry, Bioanalytical Method Validation. 2001.
43. [43] Alnouti, Y., Csanaky, I.L., Klaassen, C.D., Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC–MS/MS. J. Chromatogr. B 873 (2008), 209–217.
44. [44] Bathena, S.P.R., Mukherjee, S., Olivera, M., Alnouti, Y., The profile of bile acids and their sulfate metabolites in human urine and serum. J. Chromatogr. B 942–943 (2013), 53–62.
45. [45] Minato, K., Suzuki, M., Nagao, H., Suzuki, R., Ochiai, H., Development of analytical method for simultaneous determination of five rodent unique bile acids in rat plasma using ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. J. Chromatogr. B 1002 (2015), 399–410.
46. [46] McGill, H.C., McMahan, C.A., Malcom, G.T., Oalmann, M.C., Strong, J.P., Group, P.R., Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. Arterioscler. Thromb. Vasc. Biol. 17 (1997), 95–106.
47. [47] Toth, P.P., The good cholesterol high-density lipoprotein. Circulation 111 (2005), e89–e91.
48. [48] Glass, C., Pittman, R.C., Weinstein, D.B., Steinberg, D., Dissociation of tissue uptake of cholesterol ester from that of apoprotein AI of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc. Natl. Acad. Sci. 80 (1983), 5435–5439.
49. [49] Maxfield, F.R., Tabas, I., Role of cholesterol and lipid organization in disease. Nature 438 (2005), 612–621.
50. [50] Li, X.-Y., Zhao, Z.-X., Huang, M., Feng, R., He, C.-Y., Ma, C., Luo, S.-H., Fu, J., Wen, B.-Y., Ren, L., Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J. Transl. Med., 13, 2015, 278.
51. [51] Xie, G., Wang, Y., Wang, X., Zhao, A., Chen, T., Ni, Y., Wong, L., Zhang, H., Zhang, J., Liu, C., Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. J. Proteome Res. 14 (2015), 850–859.
52. [52] Jiang, C., Wang, Q., Wei, Y., Yao, N., Wu, Z., Ma, Y., Lin, Z., Zhao, M., Che, C., Yao, X., Cholesterol-lowering effects and potential mechanisms of different polar extracts from Cyclocarya paliurus leave in hyperlipidemic mice. J. Ethnopharmacol. 176 (2015), 17–26.
53. [53] Jelinek, D.F., Andersson, S., Slaughter, C.A., Russell, D.W., Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis. J. Biol. Chem. 265 (1990), 8190–8197.
54. [54] Jurgoński, A., Juśkiewicz, J., Zduńczyk, Z., An anthocyanin-rich extract from Kamchatka honeysuckle increases enzymatic activity within the gut and ameliorates abnormal lipid and glucose metabolism in rats. Nutrition 29 (2013), 898–902.
55. [55] Xiang, Z., Ning, Z., Scavenging and antioxidant properties of compound derived from chlorogenic acid in South-China honeysuckle. LWT-Food Sci. Technol. 41 (2008), 1189–1203.
56. [56] Wan, C.W., Wong, C.N.Y., Pin, W.K., Wong, M.H.Y., Kwok, C.Y., Chan, R.Y.K., Yu, P.H.F., Chan, S.W., Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up-regulating the gene expression of PPAR-α in hypercholesterolemic rats induced with a high-Cholesterol diet. Phytother. Res. 27 (2013), 545–551.